Do analysts rate TNON or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TNON or VERO more profitable?

Venus Concept has a net margin of -92.76% compared to Tenon Medical's net margin of -257.85%. Tenon Medical's return on equity of -907.60% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Tenon Medical -257.85% -907.60% -124.84% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts prefer BBLG or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BJDX or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VERO or DYNT?

Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERO or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Dynatronics -8.35% -41.81% -9.56%

Do analysts rate VERO or BIOL?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERO or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% BIOLASE -41.65% -1,782.73% -55.31%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 08/19/2026

Compare

VERO vs. TNON, BBLG, BJDX, DYNT, and BIOL

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include Tenon Medical (TNON), Bone Biologics (BBLG), Bluejay Diagnostics (BJDX), Dynatronics (DYNT), and BIOLASE (BIOL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to Tenon Medical?

Tenon Medical (NASDAQ:TNON) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Tenon Medical has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

In the previous week, Tenon Medical had 6 more articles in the media than Venus Concept. MarketBeat recorded 6 mentions for Tenon Medical and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 beat Tenon Medical's score of -0.19 indicating that Venus Concept is being referred to more favorably in the news media.

Company	Overall Sentiment
Tenon Medical	Neutral
Venus Concept	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tenon Medical has higher earnings, but lower revenue than Venus Concept. Tenon Medical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenon Medical	$3.94M	0.61	-$12.56M	-$44.87	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Venus Concept has a net margin of -92.76% compared to Tenon Medical's net margin of -257.85%. Tenon Medical's return on equity of -907.60% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenon Medical	-257.85%	-907.60%	-124.84%
Venus Concept	-92.76%	-1,904.25%	-85.22%

22.7% of Tenon Medical shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 17.7% of Tenon Medical shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Tenon Medical beats Venus Concept on 8 of the 15 factors compared between the two stocks.

How does Venus Concept compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics has higher earnings, but lower revenue than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Bone Biologics had 6 more articles in the media than Venus Concept. MarketBeat recorded 6 mentions for Bone Biologics and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 beat Bone Biologics' score of -0.95 indicating that Venus Concept is being referred to more favorably in the news media.

Company	Overall Sentiment
Bone Biologics	Negative
Venus Concept	Neutral

Bone Biologics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -57.87% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Bone Biologics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Bluejay Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

In the previous week, Bluejay Diagnostics had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Bluejay Diagnostics and 0 mentions for Venus Concept. Bluejay Diagnostics' average media sentiment score of 0.43 beat Venus Concept's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Venus Concept	Neutral

Bluejay Diagnostics has higher earnings, but lower revenue than Venus Concept. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Bluejay Diagnostics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bluejay Diagnostics' return on equity of -125.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
Venus Concept	-92.76%	-1,904.25%	-85.22%

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bluejay Diagnostics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Dynatronics?

Venus Concept (NASDAQ:VERO) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Dynatronics	-8.35%	-41.81%	-9.56%

Dynatronics has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 2.9% of Dynatronics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Dynatronics	Neutral

Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dynatronics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to BIOLASE?

Venus Concept (NASDAQ:VERO) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

BIOLASE has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
BIOLASE	-41.65%	-1,782.73%	-55.31%

In the previous week, BIOLASE had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for BIOLASE and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
BIOLASE	Neutral

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BIOLASE beats Venus Concept on 9 of the 13 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$442K	$5.96B	$7.37B	$12.86B
Dividend Yield	N/A	1.74%	2.53%	10.69%
P/E Ratio	-0.01	25.79	268.43	24.05
Price / Sales	0.01	65.62	621.40	92.73
Price / Cash	N/A	33.51	78.13	53.57
Price / Book	0.07	5.90	13.07	6.15
Net Income	-$47M	$148.28M	$3.46B	$347.39M
7 Day Performance	N/A	0.55%	1.43%	-0.64%
1 Month Performance	N/A	5.75%	4.58%	2.12%
1 Year Performance	-86.84%	9.08%	27.60%	20.16%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	N/A	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
TNON Tenon Medical	1.7344 of 5 stars	$5.45 +10.8%	N/A	-76.7%	$1.67M	$4.60M	N/A	8	Earnings Report Gap Down High Trading Volume
BBLG Bone Biologics	0.9949 of 5 stars	$0.64 -2.5%	N/A	-71.5%	$1.19M	N/A	N/A	2	Earnings Report Analyst Revision Gap Down
BJDX Bluejay Diagnostics	1.5197 of 5 stars	$0.97 -4.9%	N/A	-81.5%	$1.06M	N/A	N/A	9	Positive News Gap Down
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. TNON, BBLG, BJDX, DYNT, and BIOL

How does Venus Concept compare to Tenon Medical?

Summary

How does Venus Concept compare to Bone Biologics?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Summary

How does Venus Concept compare to Dynatronics?

Summary

How does Venus Concept compare to BIOLASE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. TNON, BBLG, BJDX, DYNT, and BIOL

How does Venus Concept compare to Tenon Medical?

Which has more risk and volatility, TNON or VERO?

Does the media prefer TNON or VERO?

Do analysts rate TNON or VERO?

Which has better valuation and earnings, TNON or VERO?

Is TNON or VERO more profitable?

Do insiders & institutionals believe in TNON or VERO?

Summary

How does Venus Concept compare to Bone Biologics?

Do analysts prefer BBLG or VERO?

Which has better earnings and valuation, BBLG or VERO?

Do institutionals and insiders hold more shares of BBLG or VERO?

Does the media refer more to BBLG or VERO?

Which has more volatility and risk, BBLG or VERO?

Is BBLG or VERO more profitable?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Which has more volatility & risk, BJDX or VERO?

Does the media prefer BJDX or VERO?

Which has higher valuation and earnings, BJDX or VERO?

Is BJDX or VERO more profitable?

Do insiders & institutionals hold more shares of BJDX or VERO?

Do analysts prefer BJDX or VERO?

Summary

How does Venus Concept compare to Dynatronics?

Which has more volatility & risk, VERO or DYNT?

Is VERO or DYNT more profitable?

Which has stronger valuation & earnings, VERO or DYNT?

Do institutionals & insiders hold more shares of VERO or DYNT?

Does the media favor VERO or DYNT?

Do analysts recommend VERO or DYNT?

Summary

How does Venus Concept compare to BIOLASE?

Do analysts rate VERO or BIOL?

Which has more risk and volatility, VERO or BIOL?

Which has better earnings & valuation, VERO or BIOL?

Is VERO or BIOL more profitable?

Does the media refer more to VERO or BIOL?

Do institutionals & insiders have more ownership in VERO or BIOL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools